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Background
Da bi gat ran, which is administered in a fixed dose and does not require laboratory 
monitoring, may be suitable for extended treatment of venous thromboembolism.
Methods
In two double-blind, randomized trials, we compared da bi gat ran at a dose of 150 mg 
twice daily with warfarin (active-control study) or with placebo (placebo-control 
study) in patients with venous thromboembolism who had completed at least 3 initial 
months of therapy.
Results
In the active-control study, recurrent venous thromboembolism occurred in 26 of 
1430 patients in the da bi gat ran group (1.8%) and 18 of 1426 patients in the warfarin 
group (1.3%) (hazard ratio with da bi gat ran, 1.44; 95% confidence interval [CI], 0.78 
to 2.64; P = 0.01 for noninferiority). Major bleeding occurred in 13 patients in the 
da bi gat ran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 
0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent 
with da bi gat ran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syn-
dromes occurred in 13 patients in the da bi gat ran group (0.9%) and 3 patients in the 
warfarin group (0.2%) (P = 0.02). In the placebo-control study, recurrent venous 
thromboembolism occurred in 3 of 681 patients in the da bi gat ran group (0.4%) and 
37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 
0.25; P<0.001). Major bleeding occurred in 2 patients in the da bi gat ran group (0.3%) 
and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 
36 patients in the da bi gat ran group (5.3%) and 12 patients in the placebo group 
(1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes oc-
curred in 1 patient each in the da bi gat ran and placebo groups.
Conclusions
Da bi gat ran was effective in the extended treatment of venous thromboembolism and 
carried a lower risk of major or clinically relevant bleeding than warfarin but a high-
er risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE 
ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.)
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A nticoagulant treatment with vi-tamin K antagonists is recommended for patients with venous thromboembolism.1 
Most patients receive at least 3 months of treat-
ment. Long-term treatment is recommended if 
there are risk factors for recurrence, such as mul-
tiple thrombotic episodes.1 In the absence of 
clear contraindications to anticoagulant therapy, 
the risk of major bleeding is approximately 1% 
per year with extended vitamin K antagonist ther-
apy after venous thromboembolism.2 The risk of 
major bleeding, together with the need for fre-
quent laboratory monitoring and dose adjust-
ments, makes long-term treatment problematic.
Da bi gat ran, a direct thrombin inhibitor, does 
not require frequent monitoring and dose adjust-
ments. At a dose of 150 mg twice daily, it was 
shown in one trial to be noninferior to warfarin 
for the initial 6-month treatment of venous throm-
boembolism and was associated with a lower rate 
of clinically relevant nonmajor bleeding.3 These 
findings suggested that da bi gat ran might also be 
suitable for extended therapy beyond the initial 
period of treatment. We performed two studies 
to evaluate the efficacy and safety of da bi gat ran 
during long-term prophylaxis after venous throm-
bo em bo lism. In one trial, da bi gat ran was com-
pared with warfarin (the active-control study); in 
the other trial, da bi gat ran was compared with 
placebo (the placebo-control study).
Me thods
Study Design
The active-control study was designated RE-MEDY, 
and the placebo-control study was designated 
RE-SONATE. Both studies had a randomized, 
double-blind design and enrolled patients who 
had completed at least 3 months of treatment for 
venous throm bo em bo lism. Both studies were 
funded, designed, and conducted, and the data 
analyzed, by Boehringer Ingelheim in conjunc-
tion with the steering committee, which was a 
common steering committee for the two trials. 
The members of the steering committee (the sev-
en academic authors), who had independent ac-
cess to the data, wrote the manuscript and made 
the decision to submit it for publication. The mem-
bers of the steering committee vouch for the ac-
curacy and completeness of the data and the 
analyses and for the fidelity of this report to the 
trial protocols, which are available with the full 
text of this article at NEJM.org.
Study Patients
We recruited patients for the active-control study 
from 265 sites in 33 countries and for the placebo-
control study from 147 sites in 21 countries. Pa-
tients were eligible if they were at least 18 years 
of age and had objectively confirmed, symptom-
atic, proximal deep-vein thrombosis or pulmonary 
embolism that had already been treated with an 
approved anticoagulant or if they had received 
da bi gat ran in one of two previous clinical trials of 
short-term treatment of venous throm bo em bo-
lism: the RE-COVER3 and RE-COVER II4 studies.
The main difference between the two trials in 
the selection of patients was that participants in 
the active-control study were considered to be at 
increased risk for recurrent venous thromboembo-
lism on the basis of the site investigator’s assess-
ment. The required duration of initial treatment 
before trial enrollment was 3 to 12 months for the 
active-control study and 6 to 18 months for the 
placebo-control study. Full lists of inclusion and 
exclusion criteria for each trial are provided in the 
Supplementary Appendix, available at NEJM.org.
All patients provided written informed con-
sent. The institutional review board at each par-
ticipating clinical center approved the studies.
Randomization and Treatment
In both studies, patients underwent randomiza-
tion by means of an interactive voice-response sys-
tem. Randomization was stratified according to 
the presence or absence of active cancer and ac-
cording to the index diagnosis (deep-vein throm-
bosis or pulmonary embolism) in the active-con-
trol study and according to study center in the 
placebo-control study. Prior anticoagulant therapy 
was discontinued, and the study drug was start-
ed when the international normalized ratio (INR) 
was 2.3 or lower. If the patient was enrolled from 
the RE-COVER study or the RE-COVER II study, 
a point-of-care coagulometer with encrypted INR 
results was used to guide the transition so that 
the patients and investigators would remain un-
aware of the initial treatment.
In the active-control study, patients were as-
signed in a 1:1 ratio to receive active da bi gat ran 
(at a fixed dose of 150 mg twice daily) and a 
warfarin-like placebo or active warfarin and a 
da bi gat ran-like placebo. Bilateral compression ul-
trasonography of the leg veins was performed 
within 72 hours after randomization. We ad-
justed the dose of warfarin or placebo to main-
tain an INR of 2.0 to 3.0 with the use of a point-
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of-care instrument that provided an encrypted 
INR. The true or sham INR was then obtained by 
means of an interactive voice-response system with 
a central computer that had been programmed 
with the randomization schedule.
In the placebo-control study, patients were 
assigned in a 1:1 ratio to receive da bi gat ran (at a 
fixed dose of 150 mg twice daily) or a matching 
placebo. Laboratory monitoring of coagulation was 
not performed in the placebo-control study.
Follow-up and Outcome Measures
Patients were assessed at 15 and 30 days after ran-
domization, then monthly until day 180. After that, 
patients in the active-control study were assessed 
every 90 days until the end of treatment; INR or 
sham INR results were obtained at intervals of no 
longer than 4 weeks. An additional visit occurred 
30 days after the end of treatment in both studies.
The active-control study was initially designed 
for 18 months of treatment. Because of a lower-
than-projected event rate, the protocol was amend-
ed to increase the sample and extend the planned 
treatment period for patients already enrolled who 
consented to the extension, with the resulting 
planned study treatment period ranging from 6 to 
36 months. The placebo-control study was amend-
ed, 6 months after recruitment of the first pa-
tient, to extend the follow-up to 12 months after 
completion of the study treatment to evaluate 
the long-term risk of recurrence.
In both studies, the primary efficacy outcome 
was recurrent symptomatic and objectively verified 
venous thromboembolism or death associated 
with venous thromboembolism (or unexplained 
death in the placebo-control study). Safety out-
comes included major bleeding and clinically 
relevant nonmajor bleeding. Definitions of the 
efficacy and safety outcomes are provided in the 
Supplementary Appendix. Central committees, 
whose members were not aware of the treatment 
assignments, adjudicated suspected cases of recur-
rent venous thromboembolism, bleeding, death, 
acute coronary events (as well as cerebrovascular 
events in the placebo-control study), and liver-
function abnormalities (according to clinical and 
routine laboratory data).
Statistical Analysis
The active-control study was designed to show 
that da bi gat ran is noninferior to warfarin in pre-
venting recurrent venous thromboembolism (in-
cluding death related to venous thromboembo-
lism). The sample size was determined on the 
basis of an expected rate of the primary efficacy 
outcome of 2.0% in both groups,5-8 with a power 
of 85% to exclude a hazard ratio of 2.85 (the non-
inferiority margin for the hazard ratio),3,9-14 and 
an absolute increase in the risk of recurrent ve-
nous thromboembolism of 2.8 percentage points 
at 18 months (the noninferiority margin for the 
risk difference), at a one-sided alpha level of 
0.025. To meet these specifications, we estimated 
that we would need to enroll 2000 patients. In 
the protocol amendment described above, the sam-
ple was increased to 2850 patients. Details of the 
sample-size calculation and the determination of 
the noninferiority margin are provided in the 
Supplementary Appendix.
The amended protocol for the active-control 
study resulted in a study population with a treat-
ment duration ranging from 6 to 36 months. 
Consequently, the protocol was further revised 
to group the study participants into three co-
horts according to the duration of treatment 
(<18 months, 18 months, or >18 months) and to 
perform a meta-analysis of these three cohorts 
for the primary efficacy outcome. Details of this 
analytic method are provided in the Supplemen-
tary Appendix. The prespecified analyses were 
the hazard ratio for the planned treatment pe-
riod and the risk difference at 18 months. Both 
estimates had to satisfy the noninferiority crite-
ria for da bi gat ran to be judged to be noninferior.
The placebo-control study was designed to 
determine whether da bi gat ran was superior to 
placebo for preventing recurrent venous throm-
boembolism. We assumed a 70% reduction in 
the relative risk of the primary outcome with 
da bi gat ran15 and planned for a power of 95% to 
detect this difference, at a two-sided alpha of 
0.05; on the basis of these specifications, 36 events 
were required. With an assumed frequency of 
the primary outcome of 3% at 6 months in the 
placebo group, a sample of approximately 1800 
patients was needed. The primary efficacy out-
come was analyzed with the use of a Cox pro-
portional-hazards model.
In both trials, a modified intention-to-treat 
analysis was performed for efficacy, with exclu-
sion of patients who did not receive any dose of 
the study drug. In the safety analyses, we in-
cluded all events during the period from receipt of 
the first dose of the study drug until 3 days after 
receipt of the last dose. All safety analyses and 
secondary efficacy analyses were prespecified.
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R esult s
Patients
From July 2006 through July 2010, a total of 2866 
patients underwent randomization in the active-
control study, and from November 2007 through 
September 2010, a total of 1353 patients under-
went randomization in the placebo-control study 
(Fig. S1A and S1B in the Supplementary Appen-
dix). Demographic and clinical characteristics of 
the participants in both trials are shown in Table 1.
Treatment and Follow-up
In the active-control study, one patient in each 
group mistakenly received the study drug as-
signed to the other group throughout the study. 
In the warfarin group, the INR was in the thera-
peutic range (2.0 to 3.0) for a median of 65.3% of 
the time. The INR was below the therapeutic range 
17.3% of the time and above the therapeutic 
range 12.2% of the time. Additional characteris-
tics of the treatments are provided in Table 1.
In the active-control study, the study drug was 
stopped early in 276 patients (19.3%) in the da bi-
gat ran group (in 147 because of an adverse event, 
23 because of nonadherence, 2 because of loss to 
follow-up, 64 because of their decision to stop 
taking the study medication, and 40 for other rea-
sons) and in 281 patients (19.7%) in the warfarin 
group (in 129 because of an adverse event, 34 be-
cause of nonadherence, 6 because of loss to follow-
up, 58 because of their decision to stop taking 
the study medication, and 54 for other reasons).
In the placebo-control study, 3 patients as-
signed to placebo mistakenly received da bi gat-
ran throughout the study. The study drug was 
stopped early in 71 patients (10.4%) in the da bi-
gat ran group (in 50 because of an adverse event, 
9 because of nonadherence, and 12 because of 
their decision to stop taking the study medica-
tion) and in 99 patients (15.0%) in the placebo 
group (in 81 because of an adverse event, 5 be-
cause of nonadherence, and 13 because of their 
decision to stop taking the study medication).
Table 1. Characteristics of the Patients and Treatments According to Study and Assigned Study Drug.*
Characteristic Active-Control Study Placebo-Control Study
Da bi gat ran 
(N = 1430)
Warfarin 
(N = 1426)
Da bi gat ran 
(N = 681)
Placebo 
(N = 662)
Age — yr
Mean 55.4±15.0 53.9±15.3 56.1±15.5 55.5±15.1
Range 18–92 18–93 18–89 18–91
Female sex — no. (%) 559 (39.1) 555 (38.9) 300 (44.1) 298 (45.0)
Race or ethnic group — no. (%)†
White 1288 (90.1) 1284 (90.0) 610 (89.6) 585 (88.4)
Black 29 (2.0) 28 (2.0) 9 (1.3) 14 (2.1)
Asian 113 (7.9) 114 (8.0) 58 (8.5) 60 (9.1)
American Indian 0 0 4 (0.6) 3 (0.5)
Weight — kg
Mean 86.1±19.3 86.0±18.9 83.7±18.0 84.0±18.6
Range 40–188 41–182 40–151 40–206
Estimated creatinine clearance — ml/min‡ 104.2±38.6 106.6±37.9 99.6±35.8 101.2±37.1
Type of index event — no. (%)
Deep-vein thrombosis only 938 (65.6) 922 (64.7) 431 (63.3) 441 (66.6)
Pulmonary embolism only 324 (22.7) 335 (23.5) 183 (26.9) 178 (26.9)
Both deep-vein thrombosis and pulmonary embolism 167 (11.7) 168 (11.8) 47 (6.9) 35 (5.3)
Neither deep-vein thrombosis nor pulmonary embolism§ 1 (0.1) 1 (0.1) 20 (2.9) 8 (1.2)
Immobilization — no. (%)
Transient 91 (6.4) 93 (6.5) 49 (7.2) 36 (5.4)
Permanent 3 (0.2) 12 (0.8) 4 (0.6) 0
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Efficacy and Safety in the Active-Control 
Study
The primary outcome for efficacy was confirmed 
by central adjudication in 26 patients (1.8%) in the 
da bi gat ran group and in 18 patients (1.3%) in the 
warfarin group (Table 2). The overall hazard ra-
tio with da bi gat ran for time to the first primary-
outcome event was 1.44 (95% confidence interval 
[CI], 0.78 to 2.64), and the risk difference at 18 
months was 0.38 percentage points (95% CI, −0.50 
to 1.25) (Fig. 1A), calculated with the use of the 
meta-analytic approach. In a Cox regression 
analysis of pooled individual data, the hazard ra-
tio was 1.47 (95% CI, 0.80 to 2.68). Da bi gat ran 
thus met the criteria for noninferiority to warfa-
rin with regard to the prevention of recurrent or 
fatal venous thromboembolism (P<0.001 for the 
risk-difference criterion and P = 0.01 for the hazard–
ratio criterion). There were no significant differ-
ences in efficacy according to study treatment in 
predefined subgroups (Fig. S2 in the Supplemen-
tary Appendix).
Thirteen patients (0.9%) in the da bi gat ran 
group had a major bleeding event, as compared 
with 25 patients (1.8%) in the warfarin group. 
The overall hazard ratio for time to first major 
bleeding event was 0.52 (95% CI, 0.27 to 1.02) 
(Table 2). The sites of major bleeding are pre-
sented in Table S1 in the Supplementary Appen-
dix. In both groups, 2 patients had bleeding at 
two sites. Major or clinically relevant bleeding 
occurred in 80 patients (5.6%) in the da bi gat ran 
group and 145 patients (10.2%) in the warfarin 
group (hazard ratio, 0.54; 95% CI, 0.41 to 0.71; 
P<0.001). The risk of any bleeding is shown in 
Figure 2A. There were no significant differences 
in the risk of bleeding according to study treat-
ment in predefined subgroups.
We observed a higher incidence of acute coro-
nary events in the da bi gat ran group (events in 
Table 1. (Continued.)
Characteristic Active-Control Study Placebo-Control Study
Da bi gat ran 
(N = 1430)
Warfarin 
(N = 1426)
Da bi gat ran 
(N = 681)
Placebo 
(N = 662)
Known thrombophilia — no. (%) 262 (18.3) 263 (18.4) 87 (12.8) 68 (10.3)
Active cancer — no. (%) 60 (4.2) 59 (4.1) 1¶ 2¶
Previous cancer — no. (%) NA NA 44 (6.5) 37 (5.6)
Coronary artery disease — no. (%) 120 (8.4) 87 (6.1)‖ 43 (6.3) 38 (5.7)
Diabetes mellitus — no. (%) 150 (10.5) 108 (7.6)** 57 (8.4) 50 (7.6)
Hypertension — no. (%) 582 (40.7) 520 (36.5)‖ 281 (41.3) 240 (36.3)
Treatment duration before randomization — days 198±157 200±117 293±107 299±110
Enrolled from RE-COVER study — no. (%)
Da bi gat ran group 236 (16.5) 254 (17.8) 7 (1.0) 8 (1.2)
Warfarin group 283 (19.8) 243 (17.0) 8 (1.2) 4 (0.6)
Enrolled from RE-COVER II study — no. (%) 70 (4.9) 55 (3.9) NA NA
Exposure to study drug — days 473±211 474±206 165±45 162±47
Adherence to study regimen — no. (%)†† 1386 (98.0) 1387 (98.2) 657 (96.5) 639 (96.5)
* Plus–minus values are means ±SD. All variables in each study were compared between the two groups. There were 
no significant differences between groups unless otherwise indicated. NA denotes not applicable.
† Race or ethnic group was determined by the investigator.
‡ Creatinine clearance was estimated according to the Cockcroft–Gault method.
§ In these cases, the initial diagnosis of proximal deep-vein thrombosis or pulmonary embolism was made locally but 
could not be confirmed by the central adjudication committee.
¶ Active cancer was an exclusion criterion, and the numbers represent protocol violations.
‖ P = 0.02 for the difference between the da bi gat ran group and the warfarin group, calculated with the chi-square test.
** P = 0.007 for the difference between the da bi gat ran group and the warfarin group, calculated with the chi-square test.
†† Adherence was assumed if a pill count for da bi gat ran or the da bi gat ran-like placebo indicated an intake of 80 to 120% 
of the prescribed dose. In the active-control study, this information was available for 1415 patients in the da bi gat ran 
group and 1412 patients in the warfarin group.
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13 patients [0.9%]: 10 with myocardial infarction 
and 3 with unstable angina) than in the warfarin 
group (events in 3 patients [0.2%]: 1 with myo-
cardial infarction and 2 with unstable angina). 
All these events were adjudicated as definite ex-
cept for myocardial infarction in 1 patient in the 
da bi gat ran group and unstable angina in 1 patient 
in the warfarin group. In each group, 1 patient had 
an event within 3 days after stopping the study 
treatment.
Efficacy and Safety in the Placebo-Control 
Study
The primary outcome for efficacy was confirmed 
by central adjudication in 3 patients (0.4%) in the 
da bi gat ran group and in 37 patients (5.6%) in the 
placebo group. The hazard ratio with da bi gat ran 
for time to the first primary-outcome event was 
0.08 (95% CI, 0.02 to 0.25; P<0.001) (Table 3 and 
Fig. 1B). There were no significant differences in 
efficacy according to study treatment in pre-
defined subgroups (Fig. S3 in the Supplementary 
Appendix). The extended 12-month follow-up 
was completed for 1323 of the 1343 patients who 
underwent randomization and received the study 
drug (98.5%), at which point the cumulative inci-
dence of the primary efficacy outcome was 6.9% 
in the da bi gat ran group as compared with 10.7% 
in the placebo group (hazard ratio, 0.61; 95% CI, 
0.42 to 0.88).
Table 2. Efficacy and Safety Outcomes in the Active-Control Study.*
Outcome
Da bi gat ran 
(N = 1430)
Warfarin 
(N = 1426)
Hazard Ratio 
(95% CI) P Value
no. of patients (%)
Efficacy analysis†
Primary end point of recurrent or fatal venous thrombo-
embolism
26 (1.8) 18 (1.3) 1.44 (0.78–2.64) 0.01‡
Secondary end points
Symptomatic deep-vein thrombosis 17 (1.2) 13 (0.9) 1.32 (0.64–2.71) 0.46
Symptomatic nonfatal pulmonary embolism 10 (0.7) 5 (0.4) 2.04 (0.70–5.98) 0.19
Death related to venous thromboembolism 1 (0.1) 1 (0.1) 1.01 (0.06–16.2) 0.99
All deaths 17 (1.2) 19 (1.3) 0.90 (0.47–1.72) 0.74
Safety analysis§
Major bleeding event¶ 13 (0.9) 25 (1.8) 0.52 (0.27–1.02) 0.06
Fatal event 0 1
Bleeding into critical organ 8 13
Event resulting in fall in hemoglobin level or need  
for blood transfusions
9 18
Major or clinically relevant bleeding event 80 (5.6) 145 (10.2) 0.54 (0.41–0.71) <0.001
Any bleeding event 277 (19.4) 373 (26.2) 0.71 (0.61–0.83) <0.001
Adverse event 1029 (72.0) 1010 (70.8) 0.53
Adverse event leading to discontinuation of study drug 145 (10.1) 126 (8.8) 0.26
Serious adverse event 227 (15.9) 224 (15.7) 0.97
Acute coronary syndrome
During treatment 13 (0.9) 3 (0.2) 0.02
Within 30 days after treatment 1 (0.1) 3 (0.2)
ALT >3× ULN 24 (1.7) 26 (1.8)
ALT >3× ULN and bilirubin >2× ULN 2 (0.1) 1 (0.1)
* ALT denotes alanine aminotransferase, CI confidence interval, and ULN upper limit of the normal range.
† The efficacy analysis included all randomly assigned patients who received at least one dose of the study drug and was 
based on data for the planned treatment period, regardless of whether the study drug was discontinued early.
‡ The P value for the primary outcome is for noninferiority, for which the margin was 2.85.
§ The safety analysis by default was based on the treatment period and a 3-day washout period after the end of treatment.
¶ One major bleeding event could be attributed to several of the listed criteria. The sites of the major bleeding events are 
presented in Table S1 in the Supplementary Appendix.
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There were 2 patients with major bleeding 
events, both in the da bi gat ran group; both events 
were gastrointestinal bleeding requiring at least 
2 units of blood but without a fall in the hemo-
globin level of 20 g per liter or more. Major or 
clinically relevant nonmajor bleeding occurred 
in 36 patients (5.3%) in the da bi gat ran group as 
compared with 12 patients (1.8%) in the placebo 
group (hazard ratio, 2.92; 95% CI, 1.52 to 5.60; 
P = 0.001). The risk of any bleeding is shown in 
Figure 2B. Rectal bleeding occurred in 19 patients 
(2.8%) in the da bi gat ran group and in 5 patients 
(0.8%) in the placebo group, whereas the inci-
dence of bleeding at other sites was similar in 
the two groups. In this study, there was 1 acute 
coronary event in each group.
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Figure 1. Cumulative Risk of Recurrent Venous Thromboembolism or Related Death (or Unexplained Death 
in the Placebo-Control Study).
Panel A shows data from the active-control study, and Panel B shows data from the placebo-control study.
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Discussion
We evaluated the use of da bi gat ran for the long-
term treatment of venous thromboembolism in 
two complementary randomized trials. In the 
active-control study, da bi gat ran met the pre-
defined noninferiority criteria in comparison 
with warfarin for the prevention of recurrent ve-
nous thromboembolism, with fewer major bleed-
ing events and significantly fewer clinically rele-
vant nonmajor bleeding events. As compared with 
placebo, da bi gat ran significantly reduced the rate 
of recurrent venous thromboembolism, but with 
a significantly higher risk of major or clinically 
relevant nonmajor bleeding.
In the active-control study, there was a nu-
merical increase in recurrent or fatal venous 
thromboembolic events during treatment with 
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Figure 2. Cumulative Risk of Any Bleeding.
Panel A shows data from the active-control study, and Panel B shows data from the placebo-control study.
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da bi gat ran (26 events [1.8%], vs. 18 events with 
warfarin [1.3%]). The upper limit of the 95% 
confidence interval for the hazard ratio (2.64) 
was close to the predefined noninferiority mar-
gin (2.85), and the confidence interval gives 
boundaries for the event rate with da bi gat ran as 
low as 1.0% and as high as 3.4%. This corre-
sponds to an annual risk of 0.8% to 2.6%. The 
annualized point estimates of 1.0% for warfarin 
and 1.4% for da bi gat ran can be compared with 
the annualized point estimates in previous trials 
of extended treatment with warfarin (range, 
0.7% to 5.0%)5,6,16-18 or with experimental drugs 
(ximelagatran, 1.3%; low-dose warfarin, 1.9% to 
2.6%; and rivaroxaban, 1.9%).6-9 The prespeci-
fied noninferiority margin for the hazard ratio 
of 2.85 is large, since it allows an increase in 
risk by a factor of nearly 3 to be accepted as 
noninferior. This is a limitation of the trial de-
sign. However, large noninferiority margins 
have been prespecified in trials of short-term 
treatment of venous thromboembolism with da-
bi gat ran (2.75),5,6,16-18 rivaroxaban (2.0),5,6,16-18 
and idraparinux (2.0).5,6,16-18
Table 3. Efficacy and Safety Outcomes in the Placebo-Control Study.
Outcome
Da bi gat ran 
(N = 681)
Placebo 
(N = 662)
Hazard Ratio 
(95% CI) P Value
no. of patients (%)
Efficacy analysis*
Primary end point of recurrent or fatal venous thrombo-
embolism or unexplained death
3 (0.4) 37 (5.6) 0.08 (0.02–0.25) <0.001
Secondary end points
Symptomatic deep-vein thrombosis 2 (0.3) 22 (3.3)†
Symptomatic nonfatal pulmonary embolism 1 (0.1) 14 (2.1)†
Unexplained death 0 2 (0.3)‡
Safety analysis§
Major bleeding event¶ 2 (0.3) 0 Not estimable 1.0
Event resulting in fall in hemoglobin level or need  
for blood transfusions
2 0
Major or clinically relevant bleeding event 36 (5.3) 12 (1.8) 2.92 (1.52–5.60) 0.001
Any bleeding event 72 (10.5) 39 (5.9) 1.82 (1.23–2.68) 0.003
Adverse event 346 (50.6) 324 (49.2)
Adverse event leading to discontinuation of study drug 50 (7.3) 81 (12.3)
Serious adverse event 47 (6.9) 60 (9.1)
Acute coronary syndrome during treatment‖ 1 (0.1) 1 (0.2)
Cerebrovascular event during treatment** 2 (0.3) 1 (0.2)
ALT >3× ULN†† 4 (0.6) 4 (0.6)
* The efficacy analysis included all randomly assigned patients who received at least one dose of the study drug and was 
based on data for the planned treatment period, regardless of whether the study drug was discontinued early.
† One patient in the placebo group had deep-vein thrombosis and a pulmonary embolism on the same day, and each was 
considered to be a first event.
‡ One of the two deaths occurred when the patient was not receiving the study drug. There were no cases of objectively 
verified fatal pulmonary embolism or of any other deaths.
§ The safety analysis included 684 patients who received da bi gat ran and 659 who received placebo. Three patients in the 
placebo group mistakenly received da bi gat ran throughout the study.
¶ None of the major bleeding events were fatal or occurred in a critical organ (see Table S1 in the Supplementary Appendix).
‖ There was one myocardial infarction with ST-segment elevation in the da bi gat ran group and one myocardial infarction 
without ST-segment elevation in the placebo group.
** There were two patients with transient ischemic attacks in the da bi gat ran group and one patient with ischemic stroke 
in the placebo group.
†† None of the patients had concurrent elevation of the bilirubin level of more than two times the upper limit of the nor-
mal range.
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The efficacy of da bi gat ran in comparison with 
placebo (hazard ratio, 0.08; 95% CI, 0.02 to 0.25) 
is of the same magnitude as the efficacy of riva-
roxaban versus placebo (hazard ratio, 0.18; 95% 
CI, 0.09 to 0.39)9 and of warfarin versus placebo 
or control (odds ratio, 0.05 and 0.11, respective-
ly).5,18 The benefit of extended treatment with 
da bi gat ran was maintained during the 12 months 
of extended follow-up after discontinuation of 
the study drug. The risk of clinically relevant 
bleeding with da bi gat ran as compared with pla-
cebo (hazard ratio, 2.9; 95% CI, 1.5 to 5.6) is 
similar to that of rivaroxaban as compared with 
placebo (hazard ratio, 5.2; 95% CI, 2.3 to 11.7).9
There was a higher rate of acute coronary 
events with da bi gat ran than with warfarin, with 
no significant difference in these events between 
da bi gat ran and placebo. In the Randomized Evalu-
ation of Long-Term Anticoagulation Therapy 
(RE-LY), which compared da bi gat ran and warfa-
rin in patients with atrial fibrillation, there was 
a higher risk of acute coronary syndromes with 
da bi gat ran,19 although after further analysis of 
the data this difference was no longer signifi-
cant.20,21 However, a recent meta-analysis of seven 
noninferiority trials showed a significantly high-
er risk of myocardial infarction or acute coronary 
syndromes with da bi gat ran than with the com-
parator.22 Whether da bi gat ran increases the risk of 
myocardial infarction is therefore still unclear.
In summary, we evaluated the use of da bi gat-
ran for the long-term treatment of venous throm-
boembolism in two complementary randomized 
trials. In the active-control study, da bi gat ran was 
noninferior to warfarin for the prevention of re-
current venous thromboembolism, with a lower 
risk of bleeding. In the placebo-control study, da-
bi gat ran significantly reduced the rate of recur-
rent venous thromboembolism, but with a sig-
nificantly higher risk of bleeding.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Dr. Harry Büller for contributing to the design of 
the placebo-control study.
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